Paper35257531
Medical Management of Patients With Heart Failure and Reduced Ejection Fraction.
Greenberg B. Korean Circ J, 2022. Cited by 18 papers, by iCite.
Cite this record
ConductScience Library. Medical Management of Patients With Heart Failure and Reduced Ejection Fraction. Papers, record 35257531. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35257531
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References116
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32034017 | Guideline-directed medical therapy in elderly patients with heart failure with reduced ejection fraction: a cohort study. | BMJ Open | 2020 | https://conductscience.org/library/papers/32034017 | PubMed |
| 2 | 29526832 | Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program. | Circulation | 2018 | https://conductscience.org/library/papers/29526832 | PubMed |
| 3 | 21147120 | Targeting the ACE2-Ang-(1-7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure. | J Mol Cell Cardiol | 2011 | https://conductscience.org/library/papers/21147120 | PubMed |
| 4 | 15210610 | Digitalis therapy for patients in clinical heart failure. | Circulation | 2004 | https://conductscience.org/library/papers/15210610 | PubMed |
| 5 | 13678870 | Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. | Lancet | 2003 | https://conductscience.org/library/papers/13678870 | PubMed |
| 6 | 30075873 | Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review. | J Am Coll Cardiol | 2018 | https://conductscience.org/library/papers/30075873 | PubMed |
| 7 | 30295807 | Treatments targeting inotropy. | Eur Heart J | 2019 | https://conductscience.org/library/papers/30295807 | PubMed |
| 8 | 26022006 | Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. | Eur Heart J | 2015 | https://conductscience.org/library/papers/26022006 | PubMed |
| 9 | 24164241 | Targeting sarcoplasmic reticulum calcium ATPase by gene therapy. | Hum Gene Ther | 2013 | https://conductscience.org/library/papers/24164241 | PubMed |
| 10 | 25951506 | Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure. | J Clin Pharmacol | 2015 | https://conductscience.org/library/papers/25951506 | PubMed |
| 11 | 31078482 | Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF. | JACC Heart Fail | 2019 | https://conductscience.org/library/papers/31078482 | PubMed |
| 12 | 10758966 | Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction. | J Am Coll Cardiol | 2000 | https://conductscience.org/library/papers/10758966 | PubMed |
| 13 | 8941106 | Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. | Circulation | 1996 | https://conductscience.org/library/papers/8941106 | PubMed |
| 14 | 1463530 | Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. | N Engl J Med | 1992 | https://conductscience.org/library/papers/1463530 | PubMed |
| 15 | 411364 | Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure. | Am J Cardiol | 1977 | https://conductscience.org/library/papers/411364 | PubMed |
| 16 | 3591616 | Heart rate and cardiovascular mortality: the Framingham Study. | Am Heart J | 1987 | https://conductscience.org/library/papers/3591616 | PubMed |
| 17 | 30415602 | Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. | N Engl J Med | 2019 | https://conductscience.org/library/papers/30415602 | PubMed |
| 18 | 30415601 | Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. | N Engl J Med | 2019 | https://conductscience.org/library/papers/30415601 | PubMed |
| 19 | 33095032 | Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced. | Circulation | 2021 | https://conductscience.org/library/papers/33095032 | PubMed |
| 20 | 24526677 | Matrix revisited: mechanisms linking energy substrate metabolism to the function of the heart. | Circ Res | 2014 | https://conductscience.org/library/papers/24526677 | PubMed |
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42793077 | Nanoparticle-Based Therapies for Myocardial Injury and Heart Failure: A Systematic Review and Translational Appraisal of Preclinical Evidence. | Biomolecules | 2026 | https://conductscience.org/library/papers/42793077 | PubMed |
| 42756717 | Historical Drug Costs Among Elderly Patients Hospitalized with Heart Failure in Canada, 2013-2014 to 2018-2019. | CJC Open | 2026 | https://conductscience.org/library/papers/42756717 | PubMed |
| 42486825 | [Lonicera japonica attenuates oxidative stress and improves post-ischemic heart failure in mice via the STAT3/PGC-1α axis]. | Nan Fang Yi Ke Da Xue Xue Bao | 2026 | https://conductscience.org/library/papers/42486825 | PubMed |
| 42193343 | The Influence of Basic Therapy and New Drugs on NO-Dependent Mechanisms of Cardiac Destruction in Chronic Heart Failure. | Biomedicines | 2026 | https://conductscience.org/library/papers/42193343 | PubMed |
| 41818254 | Early administration of renin-angiotensin system inhibitors improves survival and cardiac remodeling in heart failure with preserved ejection fraction. | PLoS One | 2026 | https://conductscience.org/library/papers/41818254 | PubMed |
| 40990276 | Cardiopulmonary Remodeling In Nondiabetic Patients with Systolic Heart Failure Using Sodium-Glucose Cotransporter 2 Inhibitors: An Updated Systematic Review and Meta-Analysis of Randomized Clinical Trials. | Curr Cardiol Rev | 2026 | https://conductscience.org/library/papers/40990276 | PubMed |
| 40736158 | The Biomarker Galaxy: Big Endothelin-1 Joins the Expanding Universe of Heart Failure Prognostication. | Korean Circ J | 2025 | https://conductscience.org/library/papers/40736158 | PubMed |
| 39544327 | Comprehensive Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure With Reduced Ejection Fraction: A Literature Review. | J Clin Med Res | 2024 | https://conductscience.org/library/papers/39544327 | PubMed |
| 39346567 | Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular and Renal Outcomes in Heart Failure Patients With Type 2 Diabetes: A Literature Review. | J Clin Med Res | 2024 | https://conductscience.org/library/papers/39346567 | PubMed |
| 38956938 | Proteome-wide Characterization and Pathophysiology Correlation in Non-ischemic Cardiomyopathies. | Korean Circ J | 2024 | https://conductscience.org/library/papers/38956938 | PubMed |
| 38767446 | Frailty, Sarcopenia, Cachexia, and Malnutrition in Heart Failure. | Korean Circ J | 2024 | https://conductscience.org/library/papers/38767446 | PubMed |
| 38542088 | Beyond Quadruple Therapy and Current Therapeutic Strategies in Heart Failure with Reduced Ejection Fraction: Medical Therapies with Potential to Become Part of the Therapeutic Armamentarium. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38542088 | PubMed |
| 37670168 | Novel Therapeutic Avenues for Hypertrophic Cardiomyopathy. | Am J Cardiovasc Drugs | 2023 | https://conductscience.org/library/papers/37670168 | PubMed |
| 37161744 | Treatment Strategies of Improving Quality of Care in Patients With Heart Failure. | Korean Circ J | 2023 | https://conductscience.org/library/papers/37161744 | PubMed |
| 37161685 | To Take or Not to Take: The Dilemma With Marginal Donor Heart? | Korean Circ J | 2023 | https://conductscience.org/library/papers/37161685 | PubMed |
| 35656934 | Role of β-Blockers in Chronic Coronary Artery Disease Management in the Percutaneous Coronary Intervention Era: Good Symptom Control or Something More? | Korean Circ J | 2022 | https://conductscience.org/library/papers/35656934 | PubMed |
Genes13
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35257531
GET https://conductscience.org/api/papers/v1/35257531/references?page=2